Nonclinical and clinical evaluation of monoclonal antibodies and related products intended for the prevention or treatment of COVID-19
Addendum to Annex 2 of WHO Technical Report Series, No.1048 (TRS 1059, Annex 2)
7 January 2025
| Technical document

Overview
SARS-CoV-2 is an enveloped positive-sense single-stranded RNA virus belonging to the genus Betacoronavirus. The virus first emerged in Wuhan, China in 2019, with sustained human-to-human transmission confirmed shortly afterwards, followed by its rapid spread worldwide. Evidence of sustained global transmission led WHO to declare COVID-19 a pandemic in March 2020. COVID-19 was subsequently officially declared to no longer be a public health emergency of international concern by WHO on 5 May 2023. Nevertheless, the disease remains a major threat, with SARS-CoV-2 still in circulation in most regions of the world.
WHO Team
Health Product Policy and Standards (HPS),
Norms and Standards for Biological Products (NSB),
Technical Standards and Specifications (TSS)
Number of pages
33
Copyright
World Health Organization CC BY-NC-SA 3.0 IGO